Takeda gave biopharma’s M&A bill a big boost in 2018 but to see just how slow the year was, take a look at deal volumes.
The takeovers of Loxo and Celgene put M&A back on the agenda, and positive clinical readouts from Sage and Axsome add to the celebratory mood.
Despite several changes of direction SAGE-217 comes out positive in postpartum depression, setting Sage Therapeutics up as a takeover target.
Bladder cancer data disappoint shareholders looking for signs of dose response and differentiation from Valstar.
As the curtain came down on a quarter many in biotech would rather forget, big pharma groups stood out by being the least bad investment option.
The New Year is not yet three days old, but deal-hungry investors looking forward to next week’s JP Morgan conference already have a megamerger on their hands.
Allergan, Biogen, Bristol-Myers Squibb and Lilly follow Pfizer and Merck & Co on price increases, and there could be more to come at JP Morgan.
If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.
Vantage takes a look at the sellside’s naughty and nice list for 2018: prospects improved considerably for Merck & Co’s Keytruda and Abbvie’s Mavyret, the latter…